The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

The FTC also called for legislative reforms and "is encouraged to see bipartisan interest in Congress and among the states in addressing PBM practices," according to the report. Anjalee Khemlani is ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...